证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-141 江苏恒瑞医药股份有限公司 关于与 Braveheart Bio 签署 HRS-1893 项目授权许可协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏恒瑞医药股份有限公司（以下简称"恒瑞"或"公司"）与美国 Braveheart Bio, Inc.（以下简称"Braveheart Bio"）达成协议，将具有自主知识产权的 1 类创新药 HRS-1893（以下简称"HRS-1893"）项目有偿许可给 Braveheart Bio。 一、许可产品基本信息 HRS-1893 是一种 Myosin 选择性抑制剂，可通过抑制心肌肌球蛋白三磷酸腺 苷（ATP）酶活性，从而抑制心肌过度收缩，减少左心室肥厚并改善舒张期松弛。 该药物目前正处于Ⅲ期临床开发阶段，用于治疗梗阻性肥厚型心肌病（oHCM）。 HRS-1893 其他相关情况可参见公司披露于上海证券交易所网站的《恒瑞医药关 于获得药物临床试验批准通知书的公告》（公告编号：临 2025-105）。 二 ...

格隆汇9月5日｜恒瑞医药早间公告，与美国Braveheart Bio公司达成协议，将具有自主知识产权的 1 类 创新药HRS-1893项目有偿许可给Braveheart Bio。Braveheart Bio 将向恒瑞支付6500万美元首付款和完成 技术转移后的1000万美元近期里程碑款，总计7500万美元。恒瑞有资格获得与临床开发和销售相关的里 程碑付款，最高可达10.13亿美 元。Braveheart Bio将向恒瑞支付相应的销售提成。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2025年9月5日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-141 （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了有關本公司與Braveheart ...

Group 1 - US stock market saw gains with Dow Jones up 0.77%, Nasdaq up 0.98%, and S&P 500 up 0.83% [1] - Major tech stocks performed well, with Amazon rising 4.29%, Meta up 1.57%, and Tesla increasing by 1.33% [1] - ADP reported a slowdown in US job growth with only 54,000 new jobs added in August, reinforcing expectations for a Federal Reserve rate cut [2] Group 2 - US initial jobless claims rose to 237,000, the highest level since June [2] - The US trade deficit widened to a four-month high in July as companies rushed to import goods before new tariffs [3] - A senior Federal Reserve official indicated that gradual rate cuts are appropriate, while the voting committee reiterated opposition to a rate cut in September [4] Group 3 - Trump signed a trade order imposing tariffs of up to 15% on many Japanese products, including automobiles and parts [5] - Nvidia agreed to lease AI chips from Lambda in a deal valued at $1.5 billion [7] - Nvidia's Q3 AI chip revenue exceeded expectations, growing by 63% [8] Group 4 - Huawei reintroduced its Kirin chip after four years, launching the new Mate XTs smartphone priced from 17,999 yuan [11] - The new Kirin 9020 chip offers a 36% performance improvement and is positioned between Snapdragon 8+ and Snapdragon 8 Gen 2 in terms of performance [24] - The Chinese government is encouraging the issuance of digital RMB for sports consumption and supporting the listing of qualified sports companies [10] Group 5 - The Ministry of Industry and Information Technology released a plan to boost the electronic information manufacturing industry from 2025 to 2026 [10] - The plan emphasizes the development of AI chips and encourages innovation in AI terminal applications [10] - The North Star industry is projected to reach a total output value of 500-600 billion yuan by 2025, with a compound annual growth rate exceeding 10% [27] Group 6 - Tesla's new humanoid robot, Optimus, features a gold exterior and human-like hands, indicating significant advancements in robotics [25] - The robot is expected to replace jobs that cost between $200,000 and $500,000, marking a breakthrough in productivity [25] - The company is focusing on enhancing the dexterity of its robots, with the latest version of the robot featuring 22 degrees of freedom [26]

Group 1: Industry Developments - Hainan Province is focusing on accelerating the development of the biopharmaceutical industry through enhanced government efficiency and strategic initiatives [1] - Jiangsu Zhonghui Yuantong Biotech's quadrivalent influenza subunit vaccine has received approval from NMPA, expanding its target population to include infants and the elderly [2] - Eisai and Biogen have submitted a rolling supplemental biologics license application for lecanemab to the FDA, aimed at early Alzheimer's disease patients [3] Group 2: Clinical Trials and Approvals - Lepu Medical's MWN105 injection has entered Phase II clinical trials, marking a significant step in its development [4] - Heng Rui Medicine has received approval for clinical trials of HRS-4729 injection, a novel peptide drug targeting multiple receptors [5] Group 3: Investment Activities - Sichuan Portong Medical plans to invest 150 million yuan in the Chengdu Rongchuang Fund, focusing on high-end medical devices and AI healthcare [7] - Shenzhen Mindray Technology has increased its stake in Huatai Medical to 25% through a block trade [8] - Best Idea International Limited has reduced its stake in Mengke Pharmaceutical to 8.91% due to financial needs [9] Group 4: Strategic Collaborations - Bewang Pharmaceutical and Novartis have deepened their collaboration to develop multiple cardiovascular products, including exclusive rights for certain drug candidates [10] Group 5: Product Launches - Illumina has launched Illumina Protein Prep, a product designed to enhance protein analysis in large-scale genomic studies [11] Group 6: Regulatory Actions - Sainuo Medical has received administrative regulatory measures from Tianjin Securities Regulatory Bureau due to inaccurate disclosures [12][13] Group 7: Mergers and Acquisitions - Aopu Mai is facing dissent regarding its 1.4 billion yuan acquisition plan for Chengli Bio, with concerns raised about its alignment with the company's strategic goals [14][15]

Group 1 - The company, Heng Rui Medicine, announced a share buyback of approximately 2.73 million A-shares at a cost of about 18.31 million yuan on September 4, 2025 [1]

扬子晚报网9月5日讯(记者范晓林)今天是周五，昨天北交所宏裕包材30cm4连板，安正时尚（603839）3 连板，中国瑞林（603257）4天3板。市场全天震荡走低，创业板指领跌，科创50指数跌超6%。沪深两 市全天成交额2.54万亿，较上个交易日放量1802亿。盘面上，市场热点较为杂乱，全市场近3000只个股 下跌。板块方面，零售、食品、造纸、光伏等板块涨幅居前。 标普500指数创收盘新高芯片股走强 A.利好精选 美股三大指数集体收涨，道琼斯指数涨0.77%，标普500指数涨0.83%创收盘新高，纳斯达克综合指数涨 0.98%。芯片股走强，西部数据涨超5%，美光科技涨超4%。大型科技股走强，亚马逊涨超4%，创5月 份以来最大涨幅。 恒瑞医药：获得HRS-4729注射液临床试验批准通知书 宁波建工（601789）(601789.SH)公告称，公司控股子公司市政集团及全资子公司建工集团分别为环城 南路东延快速路一期工程(主线段、富春江立交段)施工Ⅰ标段、Ⅴ标段中标单位，中标价合计11.17亿 元。 B.外围市场 恒瑞医药（600276）(600276.SH)公告称，公司及子公司福建盛迪医药有限公司收到国家药监局 ...

Core Viewpoint - The recent adjustment in the A-share market is primarily due to two factors: the accelerated upward slope of previous gains and the extreme structural differentiation in the market, necessitating a short-term consolidation phase to digest these changes [1][2][5] Market Adjustment Analysis - The market has experienced an increased adjustment amplitude, with the need for a short-term oscillation to return to a "healthy bull" state, as the previous rapid gains and increased volatility have moved the market away from its stable upward trajectory [2][5] - The current market environment requires a "slow bull" phase to achieve high-quality national development and wealth effects for residents, indicating that the market should gradually rise from the bottom [2] Structural Differentiation - The extreme structural differentiation observed in the market is detrimental to the development of a "healthy bull" market, as a stable market requires multiple sectors to perform well and alternate in their upward movements [5][7] - Recent strong performances in sectors like communication and electronics have led to significant market differentiation, which is now being corrected through a pullback in these previously strong sectors [5][7] Future Focus Areas - Future attention should be directed towards sectors with strong industrial logic and sufficient emotional digestion, including Hong Kong internet, innovative pharmaceuticals, new consumption, and new energy [7][8] - The Hong Kong internet sector is expected to benefit from multiple rebound catalysts, including a potential new round of interest rate cuts in the U.S. and positive earnings reports from major companies like Alibaba [8] - The innovative pharmaceutical sector is entering a new performance release phase, supported by industry conferences and policy adjustments, while the new consumption sector is poised to benefit from structural changes in consumer trends [9][15] - The new energy sector, having lagged behind, is expected to attract funds seeking yield flexibility, especially with upcoming technological catalysts and supportive policies [15]

Group 1 - The company, Heng Rui Medicine (01276.HK), announced a share buyback on September 4, 2025, spending RMB 18.3139 million to repurchase 270,000 A-shares [1] - The buyback price ranged from RMB 67.75 to RMB 67.97 per share [1]

Core Viewpoint - Heng Rui Medicine (600276)(01276) announced a share buyback of approximately 1.83139 million yuan for 270,000 A-shares on September 4, 2025 [1] Group 1 - The company plans to repurchase shares as part of its capital management strategy [1] - The total expenditure for the buyback is approximately 1.83139 million yuan [1] - The number of shares to be repurchased is 270,000 A-shares [1]